An investigator-initiated proof-of-concept phase II study of oral prolonged- release formulation of ketamine

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 02 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 May 2024 Results investigating the antidepressant effects of oral prolonged release formulation of racemic ketamine (KET01) in patients suffering from treatment-resistant depression (TRD) as add on therapy, published in the Journal of Psychiatric Research
18 Oct 2022 Results investigating the antidepressant effects of a novel oral prolonged-release formulation of racemic ketamine presented at the 35th Annual Congress of the European College of Neuropsychopharmacology
31 Aug 2021 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com